All Notifications

KRN Heat Exchanger: Evaluating Valuation Metrics Post-Private Placement and Market Trends

1. KRN Heat Exchanger recently completed a private placement at INR 152 per share. Following the IPO, the company will have 6.21 crore shares outstanding, leading to a valuation of approximately INR 943 crore ( P/E of 23x based on Fy24 PAT ).

2. The company's financial performance has shown remarkable growth over the past few years. Revenue surged from INR 74 crore in FY21 to an impressive INR 250 crore in FY23. In just the first six months of FY24, the revenue has already reached INR 160 crore. The Profit After Tax (PAT) has also seen significant improvement, with figures rising from INR 2 crore in FY21 to INR 10 crore in FY22, and further escalating to INR 32 crore in FY23. For the first half of FY24, the PAT stands at INR 20 crore.

3. If we annualize the PAT for FY24, it is projected to reach around INR 40 crore. Applying a Price-to-Earnings (P/E) multiple of 30x, the company's market capitalization could be valued at approximately INR 1200crore.

However, in the unlisted market, shares of KRN Heat Exchanger are currently trading at INR 360, implying a valuation of INR 2235 crore and reflecting a P/E multiple of 56x.

Dont buy

Where to contact?

Issuance of Equity Shares on Preferential Basis:

1.Number of Shares: 8,90,00,000 equity shares.

2. Issued to: AB Inbev Asia B.V., the Holding Company.

3. Price per Share: INR 47.70 (INR 10 face value + INR 37.70 premium).

4. Total Consideration: INR 424 Cr

Capital Reduction in the OTIS- Detailed Analysis

https://x.com/UnlistedZone/status/1818855246468120936

anyone interested to buy swiggy , oyo or any unlisted share plz contact only serious investors .

Veeda, providing a broad range of services across most aspects of the drug development & drug launch throughout global markets has raised capital from Sixth Sense Ventures & others. 

Founded in 2004, Veeda has grown from a single facility in 2004 to now having 4 facilities with a capability to process 1 lakh+ samples monthly. Veeda provides services across drug value chain incl BA/BE studies, full suits of Clinical trials, pharmacokinetics studies & trials in generic molecules, NCEs, large molecules & Biosimilars. 

Till date, Veeda has conducted over 3,500 trials, developed 1,000+ bio-analytical methods spread across generics, NCEs & Biosimilars & completed 85 successful regulatory audits with UK-MHRA, ANVISA & DCGI. The capital raised will be used towards Veeda’s objective of backward as well as forward integration by evaluating inorganic growth opportunities.

Latest News on Reliance Capital Resolution Plan ( 24 July 2024 )

The approval of the resolution plan submitted by IndusInd International Holdings Ltd. (“IIHL” or the “Successful Resolution Applicant”) in the corporate insolvency resolution process of Reliance Capital Limited (“RCL”) by the Hon’ble National Company Law Tribunal, Mumbai bench ("NCLT”) vide its order dated February 27, 2024 (“Approved Resolution Plan”).

Please note Reliance Capital Holds 98.67% in Reliance General Insurance. After this resolution, the IIHL will become holding company of Reliance General Insurance.

Hi,

By when IPO is expected of NSE?

Dear Shareholders,

We hope this message finds you well. Here's a brief update on our trading approval progress with BSE:

Listing Approval: Obtained from BSE in April 2024. Listing Approval 1 and Listing Approval 2.

Shares Credit Status: Filed necessary documents with CDSL/NSDL for share crediting, including capital reduction and merger actions. Delays experienced.

Next Steps: Awaiting confirmation from CDSL/NSDL. Will submit documents to BSE for trading permission immediately after.

We are committed to keeping you updated on our progress.

Best regards, ACS Tech